Education
About Us
Working with TipRanks
Follow Us
Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
XBRANE Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.13 - kr0.36
Previous CloseN/A
Volume1.93M
Average Volume (3M)21.77M
Market Cap
kr281.92M
Enterprise Valuekr313.33M
Total Cash (Recent Filing)kr44.32M
Total Debt (Recent Filing)kr49.53M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 08, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding1,532,190,300
10 Day Avg. Volume5,722,594
30 Day Avg. Volume21,774,103
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr0.13 and its highest was kr0.36 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr281.92M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Feb 20, 2025. The company reported -kr0.035 earnings per share for the quarter, missing the consensus estimate of kr0.005 by -kr0.04.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is -0.03.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 1,532,190,300 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr0.035 in its last earnings report, missing expectations of kr0.005. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
---
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB is a biopharmaceutical company, develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion. The company has two segments that are Biosimilars and Long-acting Injectables and Administration and unallocated.
---
Technical Analysis
Oncopeptides AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Isofol Medical AB
―
Intervacc AB
―
---